
Opinion|Videos|March 14, 2025
CGM's Impact on Clinical Inertia
This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does CGM adoption impact clinical inertia and support earlier therapeutic interventions across different patient populations?
- What measurable improvements have been seen with CGMs in patient outcomes (eg, glycemic control, HbA1c levels, hypoglycemic events, quality of life)?
- Because each segment is considered a separate entity, each group of discussion questions should reset with No. 1 if using numbers.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
3
Guideline-Directed Medical Therapies in Heart Failure
4
New WHO Reports Sounds Alarm on Antimicrobial Resistance
5